MOModele O. Ogunniyi

Modele O. Ogunniyi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Modele O. Ogunniyi has a total of 231 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The ACC Health Equity Heat Map

    by Amgad N. Makaryus, Robert O. Roswell, Brendan Mullen, Maghee Disch, Angela Natcheva, Akua Asare, Nausheen Akhter, Modele O. Ogunniyi, Biykem Bozkurt, Paul Douglass, et al.

  • Identifying Patients for Cardiovascular Evaluation Using Artificial Intelligence and Team-Based Care in Ghana: The H-TRIAGE Study

    by Alexis K. Okoh, Setri S. Fugar, Michael K. Amponsah, Ebru Öztürk, Alexander Adjei, Fred Adomako Boateng, Sameer Hirji, Lambert T. Appiah, Fred Stephen Sarfo, Modele O. Ogunniyi

    Background: Cardiovascular diagnostic capacity is limited in many low-resource settings. We evaluated the HeartLINK Triage for Risk-Informed Allocation and Guided Evaluation (H-TRIAGE) index, a prespecified strategy combining clinical information and AI-enabled digital auscultation to prioritize cardiovascular evaluation. Methods: In this prospective study in Ghana (February–July 2026), consecutively enrolled adults underwent a standardized assessment by trained frontline nurses and community health workers. H-TRIAGE used predefined additive symptom, vital-sign, and AI-stethoscope weights to assign Low (0–3), Intermediate (4–7), or High (≥8) Risk. Four cardiologists, blinded to H-TRIAGE, independently reviewed all participants; a fifth adjudicated disagreements. The reference standard (adjudicated indication) was a recommendation for further diagnostic testing, cardiologist-led evaluation, or both. The primary cohort comprised 5 facilities across 3 districts of the Ashanti Region; external validation used a held-out facility in a separate district of the Eastern Region. In a modeled allocation analysis, Intermediate- and High-Risk participants were considered prioritized; we calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Results: Among 3,800 participants (primary, n=3,123; external validation, n=677; median age, 52 years [IQR, 39–64]; 77.7% women), 1,707 (44.9%) had an adjudicated indication. By H-TRIAGE category, the proportion with an indication was 2.5% (Low), 87.9% (Intermediate), and 100% (High) (P for trendConclusions: H-TRIAGE accurately identified adults needing cardiologist-adjudicated evaluation, and sensitivity remained high at a geographically distinct site. Applied by frontline nurses and community health workers, it could focus scarce specialist and diagnostic capacity on the patients most likely to need it, deferring roughly half of those assessed.

  • Postpartum Monitoring for Hypertensive Disorders of Pregnancy Through Community-Clinical Linkages

    by Faith E. Metlock, Modele O. Ogunniyi, Kathryn Lindley, Garima Sharma


  • Artificial Intelligence–Enabled Digital Auscultation for Detecting Heart Failure With Reduced Ejection Fraction in Sub-Saharan Africa: The DAMSUN-HF Study

    by Alexis K. Okoh, Lambert T. Appiah, Yaw A. Wiafe, Michael K. Amponsah, Setri S. Fugar, Ebru Ozturk, Yaw Adu-Boakye, Isaac Kofi Owusu, Bernard Cudjoe Nkum, Bert-Jan van Den Born, et al.


  • Open Access

    Artificial Intelligence for Cardiovascular Care in Action

    by Dhruva Biswas, Phyllis Thangaraj, Aline F. Pedroso, Modele O. Ogunniyi, Thomas M. Maddox, Faraz S. Ahmad, Rohan Khera


  • Top Cited Papers

    Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

    by David D. Berg, Siddharth M. Patel, Paul M. Haller, Abby L. Cange, Michael G. Palazzolo, Andrea Bellavia, Julia F. Kuder, Akshay S. Desai, Silvio E. Inzucchi, John J.V. McMurray, et al.

    BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data on initiation in patients hospitalized for HF are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of in-hospital initiation of dapagliflozin (10 mg daily) in patients hospitalized for HF. The primary efficacy outcome was a composite of time to cardiovascular death or worsening HF through 2 months. Key safety outcomes included symptomatic hypotension and worsening kidney function. A prespecified meta-analysis of randomized trials evaluating initiation of SGLT2 inhibitors in patients hospitalized for HF was performed. RESULTS: Of 2401 patients (median age, 69 [Q1–Q3, 58–77] years, 815 [33.9%] women, 448 [18.7%] Black race, 1717 [71.5%] left ventricular ejection fraction ≤40%, 1074 [44.7%] newly diagnosed HF) randomized between September 2020 and March 2025, 1218 were assigned to dapagliflozin and 1183 to placebo. The primary outcome occurred in 133 patients (10.9%) in the dapagliflozin group and 150 (12.7%) in the placebo group (hazard ratio [HR], 0.86 [95% CI, 0.68–1.08]; P =0.20). A worsening HF event occurred in 115 (9.4%) and 122 (10.3%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.91 [95% CI, 0.71–1.18]). Cardiovascular death occurred in 30 (2.5%) and 37 (3.1%) patients (HR, 0.78 [95% CI, 0.48–1.27]), and death from any cause occurred in 36 (3.0%) and 53 (4.5%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.66 [95% CI, 0.43–1.00]). The rates of symptomatic hypotension were 3.6% and 2.2%, and the rates of worsening kidney function were 5.9% and 4.7% with dapagliflozin and placebo, respectively. In a meta-analysis of patients hospitalized for HF, SGLT2 inhibitors reduced the early risk of cardiovascular death or worsening HF (HR, 0.71 [95% CI, 0.54–0.93] P =0.012) and of all-cause death (HR, 0.57 [95% CI, 0.41–0.80]; P =0.001). CONCLUSIONS: In this trial, in-hospital initiation of dapagliflozin did not significantly reduce the risk of cardiovascular death or worsening HF through 2 months in hospitalized HF patients. However, the totality of randomized clinical trial data suggests that in-hospital initiation of SGLT2 inhibitors may reduce the early risk of cardiovascular death or worsening HF and of all-cause mortality. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04363697.


  • Advancing Equity in Heart Failure Outcomes

    by Apoorva Gangavelli, Rebecca S. Steinberg, Amber E. Johnson, Modele O. Ogunniyi


  • Open Access

    Health Literacy in Heart Failure

    by Ruxandra Ionescu, Larry A. Allen, Khadijah Breathett, Brian K. Fowler, Elizabeth A. Jackson, John Kundrick, Modele O. Ogunniyi, Jared W. Magnani


  • Measuring Representativeness in Clinical Trials

    by Allen Sanyi, Samuel Byiringiro, Sanaz Dabiri, Mireille Jacobson, Amanda Boyd, Modele O. Ogunniyi, Alanna A. Morris, Rachel Kohn, Neal W. Dickert, Meghan B. Lane-Fall, et al.

    Representativeness in randomized clinical trials remains a critical concern, affecting the external validity of trial results, equitable access to the risks and benefits of research participation, and public trust in clinical research. Although representative participation by members of groups traditionally underrepresented in clinical trials is just a surrogate for true diversity, equity, inclusion, and belonging in clinical trials, it can be quantified, allowing stakeholders to add empirical rigor to diversity, equity, inclusion, and belonging efforts. Multiple ways to measure representativeness have been proposed, including the participation-to-prevalence ratio, raw participation proportions or numbers for relevant subgroups, and enrollment fraction for relevant subgroups. These methods have strengths and weaknesses and may be appropriate to report in certain circumstances, depending on why stakeholders seek to assess representativeness. Stakeholders—including regulatory agencies, journal editors, clinical trial investigators, and trial sponsors—may use quantitative measures of representativeness to establish trial enrollment standards, monitor equitable participation in ongoing trials, and condition funding or drug or device approval on achieving specific representativeness targets. However, using quantitative measures of representativeness in this way could have unintended consequences, including researchers “gaming” recruitment strategies to meet target numbers, overlooking nuanced variations within communities, and potentially incentivizing problematic and exploitative recruitment strategies. Although no single method of measuring representativeness offers a comprehensive solution for increasing diversity, equity, inclusion, and belonging in all randomized clinical trials, a carefully designed, multifaceted approach to measuring representativeness may provide stakeholders with useful perspectives for measuring progress in increasing the diversity of clinical trial participation. For stakeholders seeking a single number to assess the representativeness of a trial enrolling patients with a disease state with well-delineated demographics, the participation-to-prevalence ratio is ideal; however, for a more nuanced view of representativeness, the combination of enrollment fraction in subgroups of relevance plus a full report of the demographics of patients approached for enrollment may be more appropriate.


  • Open Access

    Who Are We Missing? Reporting of Ethnicity, Race, and Sex‐Specific Populations in Clinical Trials

    by Rachel Kohn, Dorothy Sheu, Emma Britez Ferrante, Adina Lieberman, Medha R. Maitra, Josiah Drakes, Alisa J. Stephens‐Shields, Alexis K. Okoh, Alexander C. Fanaroff, Alanna A. Morris, et al.